Pre-Digested Pea Protein Releases More Potent Blood Sugar and Blood Pressure-Lowering Peptides

This was an in vitro laboratory study. Pea protein was either pre-hydrolysed with enzymes or left untreated, then subjected to simulated pepsin digestion. The resulting hydrolysates were filtered to concentrate small peptides (<10 kDa). Enzyme inhibition assays measured activity against α-amylase, α-glucosidase (both relevant to blood sugar), and ACE (relevant to blood pressure). Peptidomic analysis identified specific peptide sequences, and in silico prediction assessed their bioactive potential.

Finding natural, food-derived peptides that can help regulate blood sugar and blood pressure is a growing area of nutritional science. This study shows that how plant proteins are processed significantly affects the bioactive potential of the peptides they release. The 95% ACE inhibition is particularly striking, suggesting pea-derived peptides could eventually be developed into functional foods or supplements for cardiovascular and metabolic health.

Plant-derived bioactive peptides represent a growing alternative to synthetic drugs for managing chronic metabolic conditions. Pea protein is particularly attractive because it is widely available, affordable, and allergen-friendly compared to dairy-based peptide sources. This work advances understanding of how processing methods can optimize bioactive peptide release, bringing the field closer to developing evidence-based functional food ingredients.

This is entirely an in vitro study — enzyme inhibition in a test tube does not guarantee the same effects will occur in the human body. Peptides may be further broken down during intestinal digestion, absorbed poorly, or metabolized before reaching their target enzymes. The in silico predictions of bioactivity need validation in cell and animal models. No human or animal studies were conducted to confirm real-world health effects.